Pilar Gallego

This inventor holds 14 USPTO granted patents and 1 published patent application, plus 6 CIPO patents and 3 EPO patents. Top assignees: Pharma Mar, S.a., Pharmamar. Active years: 2006-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Pilar Gallego. Retrieved from https://idiyas.com/inventor/pilar-gallego

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 1)

% Patents Active = 71.4

CIPO Patents = 6

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 7.3

ph-index = 7

Forward Citations = 138(Granted Patents)

Location History:

Tres Cantos, ES (2008)
Madrid, ES (2006 - 2011)

Company Filing History:

Years Active: 2006-2011

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8076337 - Antitumoral derivatives of ET-743 (2011-12-13),

2. 7947671 - Synthesis of naturally occuring ecteinascidins and related compounds (2011-05-24),

3. 7919493 - Anititumoral ecteinascidin derivatives (2011-04-05),

4. 7795260 - Synthesis of naturally occurring ecteinascidins and related compounds (2010-09-14),

5. 7767659 - Synthesis of naturally occurring ecteinascidins and related compounds (2010-08-03),

6. 7763615 - Ecteinascidin analogs for use as antitumour agents (2010-07-27),

7. 7759345 - Antitumoral derivatives of ET-743 (2010-07-20),

8. 7678765 - Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them (2010-03-16),

9. 7524956 - Hemisynthetic method and new compounds (2009-04-28),

10. 7420051 - Synthetic process for the manufacture of an ecteinaschidin compound (2008-09-02),

11. 7348310 - Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them (2008-03-25),

12. 7241892 - Hemisynthetic method and new compounds (2007-07-10),

13. 7202361 - Antitumoral ecteinascidin derivatives (2007-04-10),

14. 7138547 - Antitumoral compounds (2006-11-21),

Title: Pilar Gallego: Pioneer in Antitumoral Innovation

Introduction

Pilar Gallego is a distinguished inventor based in Madrid, Spain, renowned for her substantial contributions to the field of pharmaceuticals, particularly in the development of antitumoral agents. With a remarkable portfolio of 14 patents, she has made significant strides in cancer research, underscoring her commitment to advancing medical science.

Latest Patents

Among her latest patents, Pilar Gallego has developed "Antitumoral Derivatives of ET-743," which focuses on derivatives of Et-743, Et-770, or Et-729. These derivatives have a complex general formula, wherein the substituent groups can take on various permitted meanings. Another notable patent is for the "Synthesis of Naturally Occurring Ecteinascidins and Related Compounds," where she has identified ecteinascidin compounds featuring a quinone ring known to exhibit anti-cancer properties. The work includes related processes and compounds aimed at enhancing the effectiveness of cancer treatments.

Career Highlights

Pilar Gallego has an impressive career, significantly shaped by her tenure at Pharma Mar, S.A. and Pharmamar. Her work at these companies has propelled her innovations into practical applications, enabling advancements in cancer therapeutics.

Collaborations

Throughout her career, Pilar has collaborated with notable professionals, including Ignacio Manzanares and her colleague Carmen Cuevas. These collaborations have not only enriched her research initiatives but have also fostered a productive environment for innovative thinking within the pharmaceutical industry.

Conclusion

In conclusion, Pilar Gallego stands out as a leading inventor in the realm of antitumoral innovations. Her extensive patent portfolio and collaborative efforts with esteemed colleagues reflect her dedication to advancing cancer treatment solutions. As medical research continues to evolve, Pilar's contributions will undoubtedly pave the way for future breakthroughs in the fight against cancer.

Profile summary based on public USPTO records.